Switching to TAF for hepatitis B improves kidney function and bone loss
A quarter of people with second-line ART treatment failure in Kenya have exhausted current treatment options
Generic hepatitis C drugs continue to produce high cure rates
What women want – sexual and reproductive health rights
Switching from Atripla to generic-containing regimens can produce large cost savings
AbbVie combination cures 95% of genotype 3 hepatitis C
New AbbVie hepatitis C combination cures 99% of people with cirrhosis
Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
